Delveinsight
AUGUST 6, 2020
Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. The present hATTR treatment market constitutes compounds that stabilize the TTR tetramers, a TTR-directed small interfering RNA, and a TTR-directed antisense oligonucleotide, along with supportive therapies.
pharmaphorum
DECEMBER 23, 2020
NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause. It was the third approval from Alnylam’s pipeline of RNA interference therapeutics to make it to market.
pharmaphorum
JULY 28, 2022
Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiovascular disease.
Expert insights. Personalized for you.
52 
Let's personalize your content